CCO Official Conference Coverage
|
2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 19-22, 2009 | Cape Town, South Africa
Choose from 3 tracks of coverage (mouse over track for more info)
|
Expert Highlights
These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.
 |
Hoosen Coovadia, MBBS, MD, FCP, local co-chair of IAS 2009, offers his perspective on important topics that will be covered at this conference. (7 minutes) |
 |
Download Audio |
 |
W. David Hardy, MD, offers a preview of several of the most clinically relevant studies of antiretroviral therapy to be presented at IAS 2009. (6 minutes) |
|
Download Audio |
 |
William G. Powderly, MD, reviews several studies presented at IAS 2009 that offer additional data about NRTIs and cardiovascular risk. (7 minutes) |
|
Download Audio |
 |
Glenda Gray, MBBCH, FCPaeds CSA, discusses the state of the art in biomedical prevention, focusing on microbicides, vaccines, and prevention of mother-to-child-transmission of HIV. (7 minutes) |
|
Download Audio |
 |
Myron S. Cohen, MD, Chair of the prevention section at IAS 2009, describes ongoing trials of antiretroviral therapy for prevention. (6 minutes) |
|
Download Audio |
 |
Pedro Cahn, MD, PhD, the immediate past President of the International AIDS Society, summarizes several important clinical trials and outlines new policy recommendations of the International AIDS Society.
(5 minutes) |
|
Download Audio |
 |
Richard E. Chaisson, MD, reports on current statistics of the HIV/TB combined epidemics and on new data on detection and therapy of TB, MDR- and XDR-TB in HIV-infected patients as presented at IAS 2009. (7 minutes) |
|
Download Audio |
 |
Thomas Quinn, MD, MSc, reviews several trials studying circumcision as a strategy for both prevention of transmission and acquisition of HIV infection. (9 minutes) |
|
Download Audio |
CCO Slideset
HIV/AIDS Highlights From Cape Town CCO Official Conference Coverage of the 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention
 |
|
Joseph J. Eron, Jr., MD, and Joel E. Gallant, MD, MPH, provide an overview of the most important data from the Cape Town meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.83 MB
| Date posted: 8/14/2009
|
Conference News – Reported by NAM
|
|
|
|
|
|
Click here for more news reports and to learn more about NAM. |
|
Partnership Information
|
|
|
IAS 2009 conference organizers are using a live blog, Twitter, and Facebook to communicate with delegates attending the meeting and with those following the conference from home.
IAS 2009 Live Blog
The IAS 2009 Live blog offers updates on important developments, highlights, and links to helpful resources, and features guest bloggers with their takes on key sessions and events.
Twitter, Facebook
The IAS also provides updates through a Twitter feed (@IAS2009live) and a Facebook page (Facebook registration required).
For more information about these resources and IAS 2009 go to http://www.ias2009.org/
Clinical Care Options is the official provider of online scientific analysis of IAS 2009.
|
This coverage is produced in association with the American Academy of HIV Medicine. http://www.aahivm.org
|
http://www.aidsmap.com provides comprehensive news coverage of IAS 2009, with news reports each day and a daily summary email bulletin for those who just want the highlights of the meeting.
To view the daily news coverage, and to sign up for the daily highlights bulletin (also available in French, Spanish, Portuguese and Russian) go to http://www.aidsmap.com/ias2009 |
|
Disclosures – Audio Expert Highlights
Pedro Cahn, MD, PhD, has disclosed that he has served as an advisor or speaker for Avexa, Abbott, Bristol Myers Squibb, Boehringer Ingelheim, Glaxo Smith Kline, Merck Sharp & Dohme, Pfizer, Pharmasset, Schering Plough, and Tibotec.
Richard E. Chaisson, MD, has no significant financial relationships to disclose.
Hoosen Coovadia, MBBS, MD, FCP, has no significant financial relationships to disclose.
Glenda Gray, MBBCH, FCPaeds CSA, has no significant financial relationships to disclose.
W. David Hardy, MD, has disclosed that he has received grants for research support from Biomor, Pfizer, and Tibotec; has served on advisory boards for GlaxoSmithKline, Merck, Pfizer, and Tibotec ; has served as a consultant for GlaxoSmithKline, Gilead Sciences, Pfizer, and Tibotec; and has participated in speaker bureaus for Merck and Pfizer.
William G. Powderly, MD, has disclosed that he has served on an advisory board for Boehringer Ingelheim.
Thomas Quinn, MD, MSc, has so significant financial relationships to disclose.
|
Jointly sponsored by USF Health and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
Raltegravir Plus Unboosted Atazanavir Associated With Low Rate of Virologic Failure Through 24 Weeks in Treatment-Experienced Patients
Among 27 patients treated with the NRTI-sparing regimen of twice-daily atazanavir plus raltegravir, no cases of treatment-limiting toxicity were observed and only 1 patient experienced virologic failure with raltegravir-associated resistance mutations.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|